Expenses on oncological treatments during the covid-19 pandemic in Ceará, northeast Brazil
DOI:
https://doi.org/10.21527/2176-7114.2026.51.16700Keywords:
Healthcare expenses, Neoplasms, Coronavirus, TherapeuticsAbstract
Objective: To analyze expenses related to cancer treatment during the Covid-19 pandemic in the state of Ceará. Method: A descriptive study using expense records from the Ceará Hospital Information and High Complexity Procedure Authorization System, developed in 2022. The data were synthesized using Microsoft Excel 2019®. The following measures were used for descriptive analysis: means, standard deviation, minimums, maximums, and an estimate of the mean treatment cost. Results: A reduction in expenses was identified in 2020 (R$ 3,879,505.41) and 2021 (R$ 3,088,822.14) compared to 2019. In 2020, the reduction occurred in May (R$ 2,739,116.44) and June (R$ 2,633,173.82). In 2021, the months included February (R$ 3,193,095.98), April (R$ 3,093,272.64), and May (R$ 3,093,272.64). Surgery reduced the mean values per procedure in 2020 and 2021 (R$ 3,626,046.22; R$ 3,545,102.89), followed by radiotherapy in 2020 (R$ 166,656.00) and chemotherapy (R$ 76,320.89) in 2020, with "adjuvant" treatment being reduced in both years (R$ 95,256.00; R$ 60,710.50). Conclusion: There was a slight reduction in expenses per procedure compared to pre-pandemic levels, but with a relevant assessment considering possible unmet demand during the pandemic.
References
1 Araujo SE, Leal A, Centrone AF, Teich VD, Malheiro DT, Cypriano AS, Neto MC, Klajner S. Impacto da COVID-19 sobre o atendimento de pacientes oncológicos: experiência de um centro oncológico localizado em um epicentro Latino-Americano da pandemia. Einstein (São Paulo). 2021; (19): 1-8. DOI: 10.31744/einstein_journal/2021AO6282
2 Ribeiro CM, Atty AT de M. Efeitos da Covid-19 na Atenção ao Câncer no Brasil: Impactos do Rastreamento ao Tratamento. Rev. Bras. Cancerol. [Internet]. 3º de fevereiro de 2025 [citado 6º de abril de 2025];71(1):e-074848. DOI: 10.32635/21769745.RBC.2025v71n1.4848
3 Neal R, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015; 112 (Suppl 1):92-107. DOI: doi.org/10.1038/bjc.2015.48
4 World Organization Health (WHO). Doenças Não Transmissíveis. [internet]. 2020. Available in: https://www.who.int/es/news-room/fact-sheets/detail/noncommunicable-diseases. Access in: 20 jan. 2023.
5 Rosas TV, Cazap E, Delgadom L, Ismael J, Bejarano S, Castro C, Castro H, Muller B, Gutierrez-Delgado F, Santini LA, Sologuren CV. Social Distancing and Economic Crisis During COVID-19 Pandemic Reduced Cancer Control in Latin America and Will Result in Increased Late-Stage Diagnoses and Expense. JCO Glob Oncol [serial on the internet]. 2021;7:694-703. DOI: 10.1200/GO.21.00016
6 Banco Central do Brasil. Calculadora do Cidadão. Correção de Valores. [citado em 2023 jan 20]. Disponível em: https://www3.bcb.gov.br/CALCIDADAO/publico/exibirFormCorrecaoValores.do?method=exibirFormCorrecaoValores. Acesso em: 20 jan. 2023.
7 Fundação Getúlio Vargas. Instituto Brasileiro de Economia. (FGV IBRE). Índice Geral de Precos – Mercado. [internet] 2020. Disponível em: https://portalibre.fgv.br/igp?utm_source=portal-ibre&utm_medium=menu-eu-quero&utm_campaign=portal-ibre-menu-eu-quero. Acesso em: 20 jan. 2023.
8 Gomes HMS, Nascimento JCHB, Sousa ARC, Almeida ANM. Gastos do Sistema Público de Saúde com Tratamento em Oncologia. RAHIS. 2021; 18(2):74-89. DOI: 10.21450/rahis.v18i2.6877
9 Santos HLPC, Maciel FBM, Oliveira RS. Internações Hospitalares por Neoplasias no Brasil, 2008-2018: Gastos e Tempo de Permanência. Rev. bras. Cancerol [periódico na internet]. 2020; 66(3): e-04992. DOI: 10.32635/2176-9745.RBC.2020v66n3.992
10 Lana AP, Perelman J, Andrade ELG, Acúrcio F, Guerra Junior AA, Cherchiglia ML. Cost Analysis of Cancer in Brazil: A Population-Based Study of Patients Treated by Public Health System From 2001-2015. Value Health Reg Issues. 2020; 23:137-147. DOI: 10.1016/j.vhri.2020.05.008
11 Medici AC. Custos do tratamento do câncer no Brasil: Como Melhorar o Foco. 2018. Disponível em: https://www.researchgate.net/publication/323879334_Custo_do_Tratamento_do_Cancer_no_Brasil_Como_Melhorar_o_Foco. Acesso em: 20 jan. 2023.
12 Melo N, Almeida AB, Fedozzi F, Simão FCS, Joseffi JR. Observatório de Oncologia. Custo do Câncer no Sus. 2024 maio. Disponível em: https://observatoriodeoncologia.com.br/estudos/tratamento-em-oncologia/2024/custo-do-cancer-no-sus/?utm_source=akna&utm_medium=email&utm_campaign=Observatorio-de-Oncologia-Newsletter-Custo-do-cancer-no-SUS. Acesso em: 16 jul. 2024.
13Astigueta-Pérez J, Abad-Licham M, Chávez-Chirinos C, Beraun-Milla L, Lachos-Dávila A, Diaz-Pérez E, et al. Progressão e morte da doença por câncer durante a pandemia de COVID-19: uma análise multidisciplinar para o cenário peruano. Ecancermedicalscience. 2020;14:1098. Epub 20200908. DOI: 10.3332/ecancer.2020.1098.
14União Internacional para o Controle do Câncer (UICC). Cúpula Mundial de Líderes do Câncer, 2014. The Economics of Cancer Prevention & Control Data Digest [citado 2022 jan 14]. Disponível em: https://www.uicc.org/sites/main/files/atoms/files/WCLS2014_economics_of_cancer_FINAL.pdf. Acesso em: 04 maio 2022.
15 Lago AD, Bordin R. Impacto da pandemia de covid-19 no perfil de Internações por neoplasias no brasil, 2018-2020. In: Bordin R, Camara GD. Gestão em saúde no Rio Grande do Sul: casos, análises e práticas. v. 4. Porto Alegre: Evangraf; 2022, p. 150-160.
16 Fonseca GA, Normando PG, Loureiro LVM, Rodrigues REF, Oliveira VA, Melo MDT, Santana IA. Reduction in the Number of Procedures and Hospitalizations and Increase in Cancer Mortality During the COVID-19 Pandemic in Brazil. JCO Glob Oncol [serial on the internet]. 2021 Jan [cited 2023 jan 20];7:4-9. DOI: https://doi.org/10.1200/GO.20.0047
17 Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, Mulla-Hussain L, Errihani H, Guzman RB, Mathias C, Alkayat MOF, Jradi H, Rolfo C. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. JCO Glob Oncol. 2020 Sep;6: 1428-1438. DOI: https://doi/10.1200/GO.20.00351
18 Degeling K, Baxter NN, Emery J, Jenkins MA, Franchini F, Gibbs P, Mainn GB, McArthur G, Solomon BJ, Ijzerman MJ. An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. Asia Pac J Clin Oncol. 2021;17(4):359-367. DOI: 10.1111/ajco.13505
19 Barcellos C, Xavier DR. As diferentes fases, os seus impactos e os desafios da pandemia de covid-19 no Brasil. Reciis (online). 2022;16(2):221-226. DOI: 10.29397/reciis.v16i2.3349
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Stefane Vieira Nobre, Miren Maite Uribe Arregi, Thereza Maria Magalhães Moreira , Antonio Germane Alves Pinto, Marcelo Gurgel Carlos da Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Revista Contexto & Saúde, authors agree to the following terms:
The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) license, which allows:
Share — to copy and redistribute the material in any medium or format;
Adapt — to remix, transform, and build upon the material for any purpose, including commercial.
These permissions are irrevocable, provided that the following terms are respected:
Attribution — authors must be properly credited, with a link to the license and indication of any changes made.
No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.
Notes:
The license does not apply to elements in the public domain or covered by legal exceptions.
The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).
The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.
Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.
Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.
License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.
